A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery

OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel group of oral hypoglycemic agents with multiple proven beneficial effects. However, their use has been associated with euglycemic diabetic ketoacidosis (DKA), typically triggered by risk factors such as acute illness, surgery,...

Descripción completa

Detalles Bibliográficos
Autores principales: Osafehinti, Deborah A., Okoli, Ogochukwu J., Karam, Jocelyne G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924150/
https://www.ncbi.nlm.nih.gov/pubmed/33851014
http://dx.doi.org/10.1016/j.aace.2020.11.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924150/
https://www.ncbi.nlm.nih.gov/pubmed/33851014
http://dx.doi.org/10.1016/j.aace.2020.11.014

Ejemplares similares